3/21
09:10 am
kzia
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]
High
Report
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]
3/21
08:52 am
kzia
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Medium
Report
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
3/13
08:12 am
kzia
Kazia announces presentation of new data at AACR Annual Meeting [Yahoo! Finance]
Low
Report
Kazia announces presentation of new data at AACR Annual Meeting [Yahoo! Finance]
3/13
08:00 am
kzia
Kazia announces presentation of new data at AACR Annual Meeting
Medium
Report
Kazia announces presentation of new data at AACR Annual Meeting
2/21
07:45 am
kzia
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint [Yahoo! Finance]
High
Report
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint [Yahoo! Finance]
2/21
07:30 am
kzia
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
High
Report
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint